Nalfurafine
| 220px | |
| Nalfurafine
| |
| Systematic (IUPAC) name | |
| (E)-N-[17-(cyclopropylmethyl)-4,5α-epoxy- 3,14-dihydroxymorphinan-6β-yl]-3-(furan-3-yl)- N-methylprop-2-enamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C28H32N2O5 |
| Mol. mass | 476.564 g/mol |
| Synonyms | TRK-820 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | intravenous |
Nalfurafine (INN and USAN; also known as AC-820, TRK-820) is a κ-opioid receptor agonist being developed as a treatment for uremic pruritus in people undergoing hemodialysis.
External links
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
